1. Home
  2. SLS vs AIXI Comparison

SLS vs AIXI Comparison

Compare SLS & AIXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLS
  • AIXI
  • Stock Information
  • Founded
  • SLS 2012
  • AIXI 2001
  • Country
  • SLS United States
  • AIXI China
  • Employees
  • SLS N/A
  • AIXI N/A
  • Industry
  • SLS Biotechnology: Pharmaceutical Preparations
  • AIXI Computer Software: Prepackaged Software
  • Sector
  • SLS Health Care
  • AIXI Technology
  • Exchange
  • SLS Nasdaq
  • AIXI Nasdaq
  • Market Cap
  • SLS 75.3M
  • AIXI 61.2M
  • IPO Year
  • SLS N/A
  • AIXI 2023
  • Fundamental
  • Price
  • SLS $0.90
  • AIXI $5.43
  • Analyst Decision
  • SLS
  • AIXI
  • Analyst Count
  • SLS 0
  • AIXI 0
  • Target Price
  • SLS N/A
  • AIXI N/A
  • AVG Volume (30 Days)
  • SLS 1.6M
  • AIXI 96.2K
  • Earning Date
  • SLS 11-13-2024
  • AIXI 12-24-2024
  • Dividend Yield
  • SLS N/A
  • AIXI N/A
  • EPS Growth
  • SLS N/A
  • AIXI N/A
  • EPS
  • SLS N/A
  • AIXI N/A
  • Revenue
  • SLS N/A
  • AIXI $65,643,604.00
  • Revenue This Year
  • SLS N/A
  • AIXI $22.85
  • Revenue Next Year
  • SLS N/A
  • AIXI $22.70
  • P/E Ratio
  • SLS N/A
  • AIXI N/A
  • Revenue Growth
  • SLS N/A
  • AIXI 6.22
  • 52 Week Low
  • SLS $0.50
  • AIXI $2.06
  • 52 Week High
  • SLS $1.72
  • AIXI $22.05
  • Technical
  • Relative Strength Index (RSI)
  • SLS 30.01
  • AIXI 43.93
  • Support Level
  • SLS $0.86
  • AIXI $5.34
  • Resistance Level
  • SLS $0.98
  • AIXI $6.46
  • Average True Range (ATR)
  • SLS 0.11
  • AIXI 0.48
  • MACD
  • SLS -0.02
  • AIXI -0.09
  • Stochastic Oscillator
  • SLS 21.74
  • AIXI 0.00

About SLS SELLAS Life Sciences Group Inc.

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

About AIXI XIAO-I Corporation

XIAO-I Corp is an AI industrialization company focusing on the AI Cognitive Intelligence platform. The platform combines six core technologies including Natural Language Processing, Speech Processing, Computer Vision, Machine Learning, Affective Computing, Data Intelligence, and Hyper- automation. Based on the platform, The company developed products and solutions in the fields of Al+ Contact Center, Al+ Finance, Al+ City Public Service, Al+ Architecture, Al+ Metaverse, Al+ Manufacturing, and Al+ Healthcare. It generates revenue from the sale of software products and services, M&S services, and the sale of cloud platform products.

Share on Social Networks: